Event: Where is the cancer R&D revolution headed? #JPM18

Join Endpoints and the Cancer Research Institute for a panel discussion with oncology newsmakers


Where is the cancer R&D revolution headed?

Over the past 5 years oncology research has exploded, with fast-paced development schedules delivering breakthrough drugs that are changing the standard of care. But along the way, a bubble has developed, with companies pursuing hundreds of new studies and grabbing pipeline assets in the rush to multiply checkpoint drugs and compete with therapies already on the market. Endpoints News Editor John Carroll will review some startling new data on the cancer pipeline and lead a discussion on how this revolution can best be managed — to the advantage of patients, physicians and the biopharma companies leading the boom. This is one event you won’t want to miss.

Event Details

Need help? Get help or email: help@endpointsnews.com

Panelists

placeholder

Hervé Hoppenot
CEO, Incyte

Ellen Sigal
Founder, Friends of Cancer Research

Jay Bradner
President, Novartis Institutes for BioMedical Research

placeholder

David Berman
SVP, Immuno-oncology at AstraZeneca

placeholder

Aiman Shalabi
CMO, Cancer Research Institute

Gideon Blumenthal

Gideon Blumenthal
Deputy Director (acting), Office of Hematology Oncology Products at FDA


Exclusive Sponsor

CancerResearchInstitute